BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 16832714)

  • 1. Calcitriol does not prevent bone loss in patients with asthma receiving corticosteroid therapy: a double-blind placebo-controlled trial.
    McDonald CF; Zebaze RM; Seeman E
    Osteoporos Int; 2006 Oct; 17(10):1546-51. PubMed ID: 16832714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of treatment with inhaled corticosteroids on bone mineral density of patients with asthma: related with age.
    Monadi M; Javadian Y; Cheraghi M; Heidari B; Amiri M
    Osteoporos Int; 2015 Jul; 26(7):2013-8. PubMed ID: 25860975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone mineral density and bone turnover in asthmatics treated with long-term inhaled or oral glucocorticoids.
    Ebeling PR; Erbas B; Hopper JL; Wark JD; Rubinfeld AR
    J Bone Miner Res; 1998 Aug; 13(8):1283-9. PubMed ID: 9718197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term oral corticosteroid treatment.
    Pitt P; Li F; Todd P; Webber D; Pack S; Moniz C
    Thorax; 1998 May; 53(5):351-6. PubMed ID: 9708225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clodronate is effective in preventing corticosteroid-induced bone loss among asthmatic patients.
    Herrala J; Puolijoki H; Liippo K; Raitio M; Impivaara O; Tala E; Nieminen MM
    Bone; 1998 May; 22(5):577-82. PubMed ID: 9600795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis.
    Devogelaer JP; Adler RA; Recknor C; See K; Warner MR; Wong M; Krohn K
    J Rheumatol; 2010 Jan; 37(1):141-8. PubMed ID: 19918047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial.
    Hakala M; Kröger H; Valleala H; Hienonen-Kempas T; Lehtonen-Veromaa M; Heikkinen J; Tuomiranta T; Hannonen P; Paimela L;
    Scand J Rheumatol; 2012 Aug; 41(4):260-6. PubMed ID: 22803768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin.
    Sambrook P; Birmingham J; Kelly P; Kempler S; Nguyen T; Pocock N; Eisman J
    N Engl J Med; 1993 Jun; 328(24):1747-52. PubMed ID: 7684512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial.
    Mok CC; Tong KH; To CH; Siu YP; Ma KM
    Osteoporos Int; 2008 Mar; 19(3):357-64. PubMed ID: 18038273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of inhaled corticosteroid and short courses of oral corticosteroids on bone mineral density in asthmatic patients : a 4-year longitudinal study.
    Matsumoto H; Ishihara K; Hasegawa T; Umeda B; Niimi A; Hino M
    Chest; 2001 Nov; 120(5):1468-73. PubMed ID: 11713121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.
    Choo R; Lukka H; Cheung P; Corbett T; Briones-Urbina R; Vieth R; Ehrlich L; Kiss A; Danjoux C
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1239-45. PubMed ID: 23265571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.
    Sambrook PN; Roux C; Devogelaer JP; Saag K; Lau CS; Reginster JY; Bucci-Rechtweg C; Su G; Reid DM
    Bone; 2012 Jan; 50(1):289-95. PubMed ID: 22061864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind study comparing the effects of beclomethasone and fluticasone on bone density over two years.
    Egan JJ; Maden C; Kalra S; Adams JE; Eastell R; Woodcock AA
    Eur Respir J; 1999 Jun; 13(6):1267-75. PubMed ID: 10445600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial.
    Mok CC; Ying KY; To CH; Ho LY; Yu KL; Lee HK; Ma KM
    Ann Rheum Dis; 2011 May; 70(5):778-84. PubMed ID: 21187295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids.
    Campbell IA; Douglas JG; Francis RM; Prescott RJ; Reid DM;
    Thorax; 2004 Sep; 59(9):761-8. PubMed ID: 15333852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss.
    Gallagher JC; Fowler SE; Detter JR; Sherman SS
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3618-28. PubMed ID: 11502787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind placebo-controlled study of intravenous clodronate for prevention of steroid-induced bone loss in inflammatory bowel disease.
    Abitbol V; Briot K; Roux C; Roy C; Seksik P; Charachon A; Bouhnik Y; Coffin B; Allez M; Lamarque D; Chaussade S
    Clin Gastroenterol Hepatol; 2007 Oct; 5(10):1184-9. PubMed ID: 17683996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study.
    Tee SI; Yosipovitch G; Chan YC; Chua SH; Koh ET; Chan YH; Tan SS; Tsou IY; Tan SH
    Arch Dermatol; 2012 Mar; 148(3):307-14. PubMed ID: 22105813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of tacrolimus (FK506)-based immunosuppression on bone mineral density and bone turnover after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol.
    Stempfle HU; Werner C; Siebert U; Assum T; Wehr U; Rambeck WA; Meiser B; Theisen K; Gärtner R
    Transplantation; 2002 Feb; 73(4):547-52. PubMed ID: 11889427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium.
    Sambrook PN; Kotowicz M; Nash P; Styles CB; Naganathan V; Henderson-Briffa KN; Eisman JA; Nicholson GC
    J Bone Miner Res; 2003 May; 18(5):919-24. PubMed ID: 12733733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.